NOVO NORDISK A/S This material is intended for global medical media only.
For journalistic assessment and preparation before publication.
Novo Nordisk to present 53 abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LABagsværd, Denmark, 6 June 2016 - Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from 10-14 June.
Following are key highlights that will be presented at the meeting: 12 June, 8.30 am CDT, oral presentation
Phase 3a results from the SUSTAIN 2 clinical study comparing the efficacy and safety of semaglutide with sitagliptin in people with type 2 diabetes (#185-OR)
12 June, 9.00 am CDT, oral presentation
Phase 3a results from the SUSTAIN 3 clinical study comparing the efficacy and safety of semaglutide with exenatide extended release (ER) in people with type 2 diabetes (#187-OR)
12 June, 12.00 pm CDT, poster presentation
Phase 3b results from the SWITCH clinical studies comparing the hypoglycaemia occurrence in people with type 1 diabetes on basal-bolus insulin and type 2 diabetes on basal insulin treated with Tresiba® (insulin degludec injection 100 Units/mL) vs insulin glargine U-100 in a blinded setting (#87-LB and #90-LB)
12 June, 3.00 pm CDT and 13 June, 8.45 am CDT, oral presentations
Phase 3a results from the onset clinical trials evaluating the efficacy of faster- acting insulin aspart vs insulin aspart in people with type 1 and type 2 diabetes (#293-OR, #240-OR)
June, 2.45 pm CDT, oral presentation
Results from DUAL V on IDegLira vs insulin glargine U-100 comparing safety and efficacy in patients with uncontrolled type 2 diabetes (#239-OR)
June, 2.15 pm CDT, oral presentation
Results from LEADER, a cardiovascular outcomes trial which investigated the cardiovascular safety of Victoza® (liraglutide) injection in people with type 2 diabetes at high risk of major adverse cardiovascular events
Corporate Communications
Novo Allé
2880 Bagsværd Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Page 2 of 2
11 June, 12.30 pm CDT, moderated poster discussion; 13 June, 12.00 pm CDT, poster presentation
Data from the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) Study relating to 'Concerns about Hypoglycemia' (#667-P)
"ADA 2016 will be a landmark congress for Novo Nordisk. This year, we have an unprecedented amount of key clinical data on our new insulins and GLP-1, and we look forward to sharing it all with the medical and scientific community," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The presented research demonstrates advances in several areas of diabetes, underscoring our focus on developing innovative treatments with the potential to improve the lives of people with diabetes."
The above abstracts are a sampling of the data that will be presented or published by Novo Nordisk. For a complete list of abstracts please click here: http://www.abstractsonline.com/pp8/#!/4008.
This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit www.novonordisk.us.
About Novo NordiskNovo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Media: | ||
Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
Åsa Josefsson | +45 3079 7708 | aajf@novonordisk.com |
Michael Bachner | +1 609 664 7308 | mzyb@novonordisk.com |
Chris Clark | +1 609 619 1831 | cpcr@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Corporate Communications
Novo Allé
2880 Bagsværd Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Novo Nordisk A/S published this content on 06 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 June 2016 12:04:11 UTC.
Original documenthttp://www.novonordisk.com/bin/getPDF.2018092.pdf
Public permalinkhttp://www.publicnow.com/view/3E27DF46A5D34F4511A46726A05C3EFC777CD106
